Treatment options for 2009 H1N1 influenza: evaluation of the published evidence
Identifieur interne : 000263 ( Hal/Checkpoint ); précédent : 000262; suivant : 000264Treatment options for 2009 H1N1 influenza: evaluation of the published evidence
Auteurs : Matthew E. Falagas [Grèce] ; Evridiki K. Vouloumanou [Grèce] ; Evagelia Baskouta [Grèce] ; Petros I. Rafailidis [Grèce] ; Kostantinos Polyzos [Grèce] ; Jordi Rello [Espagne]Source :
- International Journal of Antimicrobial Agents [ 0924-8579 ] ; 2010-03-19.
Abstract
We evaluated the evidence regarding the effectiveness of various treatment strategies used for 2009 H1N1 influenza by reviewing available relevant studies. In total, 22 studies (15 cohort studies involving >10 patients, 5 cohort studies with ≤10 patients and 2 case reports) were included. A total of 3020 patients [1068 (35.4%) critically ill, 1722 (57.0%) hospitalised and 230 (7.6%) outpatients, including 909 (30.1%) children] were involved. Notably, 487 (16.1%) were obese [body mass index (BMI) >30)], 362 (12.0%) had asthma or chronic obstructive pulmonary disease and 255 (8.4%) were pregnant. Antiviral treatment was administered to 1622 patients (53.7%), of whom 661 (40.8%) received oseltamivir monotherapy. Corticosteroids were administered in 323 (31.8%) of 1016 patients for whom relevant data were available. Similarly, 633 (85.0%) of 745 patients received antibiotics. Comparative data from the largest included study (involving 1088 patients) indicated that administration of antivirals within 2 days from symptom onset was significantly associated with reduced mortality (<0.001). In summary, the scarcity of comparative available data hampered the establishment of any firm conclusions regarding the benefit that various treatment strategies may confer to patients with 2009 H1N1 influenza. Studies with a comparative design as well as randomised studies are needed to clarify further this issue of major importance.
Url:
DOI: 10.1016/j.ijantimicag.2010.01.006
Links toward previous steps (curation, corpus...)
Links to Exploration step
Hal:hal-00578292Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment options for 2009 H1N1 influenza: evaluation of the published evidence</title>
<author><name sortKey="Falagas, Matthew E" sort="Falagas, Matthew E" uniqKey="Falagas M" first="Matthew E." last="Falagas">Matthew E. Falagas</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-140123" status="INCOMING"> <orgName>Alfa Institute of Biomedical Sciences (AIBS)</orgName>
<desc> <address> <country key="GR"></country>
</address>
</desc>
<listRelation> <relation active="#struct-326908" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-326908" type="direct"><org type="institution" xml:id="struct-326908" status="INCOMING"> <orgName>Alfa Institute of Biomedical Sciences (AIBS)</orgName>
<desc> <address> <country key="FR"></country>
</address>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>Grèce</country>
</affiliation>
</author>
<author><name sortKey="Vouloumanou, Evridiki K" sort="Vouloumanou, Evridiki K" uniqKey="Vouloumanou E" first="Evridiki K." last="Vouloumanou">Evridiki K. Vouloumanou</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-140123" status="INCOMING"> <orgName>Alfa Institute of Biomedical Sciences (AIBS)</orgName>
<desc> <address> <country key="GR"></country>
</address>
</desc>
<listRelation> <relation active="#struct-326908" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-326908" type="direct"><org type="institution" xml:id="struct-326908" status="INCOMING"> <orgName>Alfa Institute of Biomedical Sciences (AIBS)</orgName>
<desc> <address> <country key="FR"></country>
</address>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>Grèce</country>
</affiliation>
</author>
<author><name sortKey="Baskouta, Evagelia" sort="Baskouta, Evagelia" uniqKey="Baskouta E" first="Evagelia" last="Baskouta">Evagelia Baskouta</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-140123" status="INCOMING"> <orgName>Alfa Institute of Biomedical Sciences (AIBS)</orgName>
<desc> <address> <country key="GR"></country>
</address>
</desc>
<listRelation> <relation active="#struct-326908" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-326908" type="direct"><org type="institution" xml:id="struct-326908" status="INCOMING"> <orgName>Alfa Institute of Biomedical Sciences (AIBS)</orgName>
<desc> <address> <country key="FR"></country>
</address>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>Grèce</country>
</affiliation>
</author>
<author><name sortKey="Rafailidis, Petros I" sort="Rafailidis, Petros I" uniqKey="Rafailidis P" first="Petros I." last="Rafailidis">Petros I. Rafailidis</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-140123" status="INCOMING"> <orgName>Alfa Institute of Biomedical Sciences (AIBS)</orgName>
<desc> <address> <country key="GR"></country>
</address>
</desc>
<listRelation> <relation active="#struct-326908" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-326908" type="direct"><org type="institution" xml:id="struct-326908" status="INCOMING"> <orgName>Alfa Institute of Biomedical Sciences (AIBS)</orgName>
<desc> <address> <country key="FR"></country>
</address>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>Grèce</country>
</affiliation>
</author>
<author><name sortKey="Polyzos, Kostantinos" sort="Polyzos, Kostantinos" uniqKey="Polyzos K" first="Kostantinos" last="Polyzos">Kostantinos Polyzos</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-140123" status="INCOMING"> <orgName>Alfa Institute of Biomedical Sciences (AIBS)</orgName>
<desc> <address> <country key="GR"></country>
</address>
</desc>
<listRelation> <relation active="#struct-326908" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-326908" type="direct"><org type="institution" xml:id="struct-326908" status="INCOMING"> <orgName>Alfa Institute of Biomedical Sciences (AIBS)</orgName>
<desc> <address> <country key="FR"></country>
</address>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>Grèce</country>
</affiliation>
</author>
<author><name sortKey="Rello, Jordi" sort="Rello, Jordi" uniqKey="Rello J" first="Jordi" last="Rello">Jordi Rello</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-150013" status="INCOMING"> <orgName>Critical Care Department</orgName>
<desc> <address> <country key="ES"></country>
</address>
</desc>
<listRelation> <relation active="#struct-337694" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-337694" type="direct"><org type="institution" xml:id="struct-337694" status="INCOMING"> <orgName>Joan XXIII University Hospital</orgName>
<desc> <address> <country key="FR"></country>
</address>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>Espagne</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">HAL</idno>
<idno type="RBID">Hal:hal-00578292</idno>
<idno type="halId">hal-00578292</idno>
<idno type="halUri">https://hal.archives-ouvertes.fr/hal-00578292</idno>
<idno type="url">https://hal.archives-ouvertes.fr/hal-00578292</idno>
<idno type="doi">10.1016/j.ijantimicag.2010.01.006</idno>
<date when="2010-03-19">2010-03-19</date>
<idno type="wicri:Area/Hal/Corpus">000305</idno>
<idno type="wicri:Area/Hal/Curation">000305</idno>
<idno type="wicri:Area/Hal/Checkpoint">000263</idno>
<idno type="wicri:explorRef" wicri:stream="Hal" wicri:step="Checkpoint">000263</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Treatment options for 2009 H1N1 influenza: evaluation of the published evidence</title>
<author><name sortKey="Falagas, Matthew E" sort="Falagas, Matthew E" uniqKey="Falagas M" first="Matthew E." last="Falagas">Matthew E. Falagas</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-140123" status="INCOMING"> <orgName>Alfa Institute of Biomedical Sciences (AIBS)</orgName>
<desc> <address> <country key="GR"></country>
</address>
</desc>
<listRelation> <relation active="#struct-326908" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-326908" type="direct"><org type="institution" xml:id="struct-326908" status="INCOMING"> <orgName>Alfa Institute of Biomedical Sciences (AIBS)</orgName>
<desc> <address> <country key="FR"></country>
</address>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>Grèce</country>
</affiliation>
</author>
<author><name sortKey="Vouloumanou, Evridiki K" sort="Vouloumanou, Evridiki K" uniqKey="Vouloumanou E" first="Evridiki K." last="Vouloumanou">Evridiki K. Vouloumanou</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-140123" status="INCOMING"> <orgName>Alfa Institute of Biomedical Sciences (AIBS)</orgName>
<desc> <address> <country key="GR"></country>
</address>
</desc>
<listRelation> <relation active="#struct-326908" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-326908" type="direct"><org type="institution" xml:id="struct-326908" status="INCOMING"> <orgName>Alfa Institute of Biomedical Sciences (AIBS)</orgName>
<desc> <address> <country key="FR"></country>
</address>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>Grèce</country>
</affiliation>
</author>
<author><name sortKey="Baskouta, Evagelia" sort="Baskouta, Evagelia" uniqKey="Baskouta E" first="Evagelia" last="Baskouta">Evagelia Baskouta</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-140123" status="INCOMING"> <orgName>Alfa Institute of Biomedical Sciences (AIBS)</orgName>
<desc> <address> <country key="GR"></country>
</address>
</desc>
<listRelation> <relation active="#struct-326908" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-326908" type="direct"><org type="institution" xml:id="struct-326908" status="INCOMING"> <orgName>Alfa Institute of Biomedical Sciences (AIBS)</orgName>
<desc> <address> <country key="FR"></country>
</address>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>Grèce</country>
</affiliation>
</author>
<author><name sortKey="Rafailidis, Petros I" sort="Rafailidis, Petros I" uniqKey="Rafailidis P" first="Petros I." last="Rafailidis">Petros I. Rafailidis</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-140123" status="INCOMING"> <orgName>Alfa Institute of Biomedical Sciences (AIBS)</orgName>
<desc> <address> <country key="GR"></country>
</address>
</desc>
<listRelation> <relation active="#struct-326908" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-326908" type="direct"><org type="institution" xml:id="struct-326908" status="INCOMING"> <orgName>Alfa Institute of Biomedical Sciences (AIBS)</orgName>
<desc> <address> <country key="FR"></country>
</address>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>Grèce</country>
</affiliation>
</author>
<author><name sortKey="Polyzos, Kostantinos" sort="Polyzos, Kostantinos" uniqKey="Polyzos K" first="Kostantinos" last="Polyzos">Kostantinos Polyzos</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-140123" status="INCOMING"> <orgName>Alfa Institute of Biomedical Sciences (AIBS)</orgName>
<desc> <address> <country key="GR"></country>
</address>
</desc>
<listRelation> <relation active="#struct-326908" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-326908" type="direct"><org type="institution" xml:id="struct-326908" status="INCOMING"> <orgName>Alfa Institute of Biomedical Sciences (AIBS)</orgName>
<desc> <address> <country key="FR"></country>
</address>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>Grèce</country>
</affiliation>
</author>
<author><name sortKey="Rello, Jordi" sort="Rello, Jordi" uniqKey="Rello J" first="Jordi" last="Rello">Jordi Rello</name>
<affiliation wicri:level="1"><hal:affiliation type="laboratory" xml:id="struct-150013" status="INCOMING"> <orgName>Critical Care Department</orgName>
<desc> <address> <country key="ES"></country>
</address>
</desc>
<listRelation> <relation active="#struct-337694" type="direct"></relation>
</listRelation>
<tutelles><tutelle active="#struct-337694" type="direct"><org type="institution" xml:id="struct-337694" status="INCOMING"> <orgName>Joan XXIII University Hospital</orgName>
<desc> <address> <country key="FR"></country>
</address>
</desc>
</org>
</tutelle>
</tutelles>
</hal:affiliation>
<country>Espagne</country>
</affiliation>
</author>
</analytic>
<idno type="DOI">10.1016/j.ijantimicag.2010.01.006</idno>
<series><title level="j">International Journal of Antimicrobial Agents</title>
<idno type="ISSN">0924-8579</idno>
<imprint><date type="datePub">2010-03-19</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="mix" xml:lang="it"><term>Mortality</term>
<term>Neuraminidase inhibitors</term>
<term>Oseltamivir</term>
<term>Pandemic influenza</term>
<term>Steroids</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"> <p>We evaluated the evidence regarding the effectiveness of various treatment strategies used for 2009 H1N1 influenza by reviewing available relevant studies. In total, 22 studies (15 cohort studies involving >10 patients, 5 cohort studies with ≤10 patients and 2 case reports) were included. A total of 3020 patients [1068 (35.4%) critically ill, 1722 (57.0%) hospitalised and 230 (7.6%) outpatients, including 909 (30.1%) children] were involved. Notably, 487 (16.1%) were obese [body mass index (BMI) >30)], 362 (12.0%) had asthma or chronic obstructive pulmonary disease and 255 (8.4%) were pregnant. Antiviral treatment was administered to 1622 patients (53.7%), of whom 661 (40.8%) received oseltamivir monotherapy. Corticosteroids were administered in 323 (31.8%) of 1016 patients for whom relevant data were available. Similarly, 633 (85.0%) of 745 patients received antibiotics. Comparative data from the largest included study (involving 1088 patients) indicated that administration of antivirals within 2 days from symptom onset was significantly associated with reduced mortality (<0.001). In summary, the scarcity of comparative available data hampered the establishment of any firm conclusions regarding the benefit that various treatment strategies may confer to patients with 2009 H1N1 influenza. Studies with a comparative design as well as randomised studies are needed to clarify further this issue of major importance.</p>
</div>
</front>
</TEI>
<hal api="V3"> <titleStmt> <title xml:lang="en">Treatment options for 2009 H1N1 influenza: evaluation of the published evidence</title>
<author role="crp"> <persName> <forename type="first">Matthew E.</forename>
<surname>Falagas</surname>
</persName>
<email type="md5">068f639e3766375670bc55ba50fdab2b</email>
<email type="domain">aibs.gr</email>
<idno type="halauthorid">544374</idno>
<affiliation ref="#struct-140123"></affiliation>
<affiliation ref="#struct-140124"></affiliation>
<affiliation ref="#struct-150012"></affiliation>
</author>
<author role="aut"> <persName> <forename type="first">Evridiki K.</forename>
<surname>Vouloumanou</surname>
</persName>
<idno type="halauthorid">584512</idno>
<affiliation ref="#struct-140123"></affiliation>
</author>
<author role="aut"> <persName> <forename type="first">Evagelia</forename>
<surname>Baskouta</surname>
</persName>
<idno type="halauthorid">593511</idno>
<affiliation ref="#struct-140123"></affiliation>
</author>
<author role="aut"> <persName> <forename type="first">Petros I.</forename>
<surname>Rafailidis</surname>
</persName>
<idno type="halauthorid">568732</idno>
<affiliation ref="#struct-140123"></affiliation>
</author>
<author role="aut"> <persName> <forename type="first">Kostantinos</forename>
<surname>Polyzos</surname>
</persName>
<idno type="halauthorid">593512</idno>
<affiliation ref="#struct-140123"></affiliation>
</author>
<author role="aut"> <persName> <forename type="first">Jordi</forename>
<surname>Rello</surname>
</persName>
<idno type="halauthorid">593513</idno>
<affiliation ref="#struct-150013"></affiliation>
</author>
<editor role="depositor"> <persName> <forename>Hal</forename>
<surname>Peer</surname>
</persName>
<email type="md5">86d0524708364ec39d879b6988476a91</email>
<email type="domain">inria.fr</email>
</editor>
</titleStmt>
<editionStmt> <edition n="v1" type="current"> <date type="whenSubmitted">2011-03-19 02:54:56</date>
<date type="whenWritten">2009-12-24</date>
<date type="whenModified">2011-03-19 02:54:56</date>
<date type="whenReleased">2011-03-19 02:54:56</date>
<date type="whenProduced">2010-03-19</date>
<date type="whenEndEmbargoed">2011-03-19</date>
<ref type="file" target="https://hal.archives-ouvertes.fr/hal-00578292/document"> <date notBefore="2011-03-19"></date>
</ref>
<ref type="file" subtype="author" n="1" target="https://hal.archives-ouvertes.fr/hal-00578292/file/PEER_stage2_10.1016%252Fj.ijantimicag.2010.01.006.pdf"> <date notBefore="2011-03-19"></date>
</ref>
<ref type="externalLink" target="https://hal.archives-ouvertes.fr/hal-00578292/document"></ref>
</edition>
<respStmt> <resp>contributor</resp>
<name key="148147"> <persName> <forename>Hal</forename>
<surname>Peer</surname>
</persName>
<email type="md5">86d0524708364ec39d879b6988476a91</email>
<email type="domain">inria.fr</email>
</name>
</respStmt>
</editionStmt>
<publicationStmt> <distributor>CCSD</distributor>
<idno type="halId">hal-00578292</idno>
<idno type="halUri">https://hal.archives-ouvertes.fr/hal-00578292</idno>
<idno type="halBibtex">falagas:hal-00578292</idno>
<idno type="halRefHtml">International Journal of Antimicrobial Agents, Elsevier, 2010, 35 (5), pp.421. ⟨10.1016/j.ijantimicag.2010.01.006⟩</idno>
<idno type="halRef">International Journal of Antimicrobial Agents, Elsevier, 2010, 35 (5), pp.421. ⟨10.1016/j.ijantimicag.2010.01.006⟩</idno>
</publicationStmt>
<seriesStmt> <idno type="stamp" n="PEER">PEER Publishing and the Ecology of European Research</idno>
</seriesStmt>
<notesStmt> <note type="audience" n="2">International</note>
<note type="popular" n="0">No</note>
<note type="peer" n="1">Yes</note>
</notesStmt>
<sourceDesc> <biblStruct> <analytic> <title xml:lang="en">Treatment options for 2009 H1N1 influenza: evaluation of the published evidence</title>
<author role="crp"> <persName> <forename type="first">Matthew E.</forename>
<surname>Falagas</surname>
</persName>
<email type="md5">068f639e3766375670bc55ba50fdab2b</email>
<email type="domain">aibs.gr</email>
<idno type="halauthorid">544374</idno>
<affiliation ref="#struct-140123"></affiliation>
<affiliation ref="#struct-140124"></affiliation>
<affiliation ref="#struct-150012"></affiliation>
</author>
<author role="aut"> <persName> <forename type="first">Evridiki K.</forename>
<surname>Vouloumanou</surname>
</persName>
<idno type="halauthorid">584512</idno>
<affiliation ref="#struct-140123"></affiliation>
</author>
<author role="aut"> <persName> <forename type="first">Evagelia</forename>
<surname>Baskouta</surname>
</persName>
<idno type="halauthorid">593511</idno>
<affiliation ref="#struct-140123"></affiliation>
</author>
<author role="aut"> <persName> <forename type="first">Petros I.</forename>
<surname>Rafailidis</surname>
</persName>
<idno type="halauthorid">568732</idno>
<affiliation ref="#struct-140123"></affiliation>
</author>
<author role="aut"> <persName> <forename type="first">Kostantinos</forename>
<surname>Polyzos</surname>
</persName>
<idno type="halauthorid">593512</idno>
<affiliation ref="#struct-140123"></affiliation>
</author>
<author role="aut"> <persName> <forename type="first">Jordi</forename>
<surname>Rello</surname>
</persName>
<idno type="halauthorid">593513</idno>
<affiliation ref="#struct-150013"></affiliation>
</author>
</analytic>
<monogr> <idno type="halJournalId" status="VALID">14335</idno>
<idno type="issn">0924-8579</idno>
<title level="j">International Journal of Antimicrobial Agents</title>
<imprint> <publisher>Elsevier</publisher>
<biblScope unit="volume">35</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="pp">421</biblScope>
<date type="datePub">2010-03-19</date>
</imprint>
</monogr>
<idno type="doi">10.1016/j.ijantimicag.2010.01.006</idno>
</biblStruct>
</sourceDesc>
<profileDesc> <langUsage> <language ident="en">English</language>
</langUsage>
<textClass> <keywords scheme="author"> <term xml:lang="it">Pandemic influenza</term>
<term xml:lang="it">Neuraminidase inhibitors</term>
<term xml:lang="it">Oseltamivir</term>
<term xml:lang="it">Steroids</term>
<term xml:lang="it">Mortality</term>
</keywords>
<classCode scheme="halTypology" n="ART">Journal articles</classCode>
</textClass>
<abstract xml:lang="en"> <p>We evaluated the evidence regarding the effectiveness of various treatment strategies used for 2009 H1N1 influenza by reviewing available relevant studies. In total, 22 studies (15 cohort studies involving >10 patients, 5 cohort studies with ≤10 patients and 2 case reports) were included. A total of 3020 patients [1068 (35.4%) critically ill, 1722 (57.0%) hospitalised and 230 (7.6%) outpatients, including 909 (30.1%) children] were involved. Notably, 487 (16.1%) were obese [body mass index (BMI) >30)], 362 (12.0%) had asthma or chronic obstructive pulmonary disease and 255 (8.4%) were pregnant. Antiviral treatment was administered to 1622 patients (53.7%), of whom 661 (40.8%) received oseltamivir monotherapy. Corticosteroids were administered in 323 (31.8%) of 1016 patients for whom relevant data were available. Similarly, 633 (85.0%) of 745 patients received antibiotics. Comparative data from the largest included study (involving 1088 patients) indicated that administration of antivirals within 2 days from symptom onset was significantly associated with reduced mortality (<0.001). In summary, the scarcity of comparative available data hampered the establishment of any firm conclusions regarding the benefit that various treatment strategies may confer to patients with 2009 H1N1 influenza. Studies with a comparative design as well as randomised studies are needed to clarify further this issue of major importance.</p>
</abstract>
</profileDesc>
</hal>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Hal/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000263 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Hal/Checkpoint/biblio.hfd -nk 000263 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= H2N2V1 |flux= Hal |étape= Checkpoint |type= RBID |clé= Hal:hal-00578292 |texte= Treatment options for 2009 H1N1 influenza: evaluation of the published evidence }}
This area was generated with Dilib version V0.6.33. |